Hypotheses that CTLA-4 blockade could enhance anti-tumor response were tested by a pre- clinical study using transplantable murine melanoma cell lines, demonstrating that CTLA-4 inhibitors induced rejection of melanoma (21). The gene discussed is CTLA4; the disease is melanoma.